Novoste Parrying Drug-Coated Stents With Planned Indications For Beta-Cath
This article was originally published in The Gray Sheet
Executive Summary
Novoste will rely on supplemental indications unaddressed by drug-coated stent developers to increase adoption of its Beta-Cath vascular brachytherapy system.